Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists want to test a new medicine called Selinexor for people who have a type of cancer called relapsed and refractory multiple myeloma (RRMM). The medicine is supposed to stop the cancer cells from spreading. The scientists will compare how well the medicine works when combined with different other medicines. They will choose which combination of medicines each person will get. Then they will see if the medicine works better with one combination or another.
Scientists want to test a new medicine called Selinexor for people who have a type of cancer called relapsed and refractory multiple myeloma (RRMM). The medicine is supposed to stop the cancer cells from spreading. The scientists will compare how well the medicine works when combined with different other medicines. They will choose which combination of medicines each person will get. Then they will see if the medicine works better with one combination or another.
*Third Opinion AI Generated Synopsis
Trial Summary
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of the following treatment arms: Arm 1: Selinexor + pomalidomide + dexamethasone (SPd) Arm 2: Selinexor + daratumumab + dexamethasone (SDd) Arm 3: Selinexor + carfilzomib + dexamethasone (SKd)
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of the following treatment arms: Arm 1: Selinexor + pomalidomide + dexamethasone (SPd) Arm 2: Selinexor + daratumumab + dexamethasone (SDd) Arm 3: Selinexor + carfilzomib + dexamethasone (SKd)
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: